Abstract
Background
Palmar-plantar erythrodysesthesia (PPE) is a slowly developing cutaneous reaction commonly experienced by patients treated with fluoropyrimidines. While erythrodysesthesia normally presents in a palmar-plantar distribution, it can also present with genital involvement, but this presentation is likely underreported and incorrectly attributed to an acute reaction from radiation therapy. This article aims to define erythrodysesthesia of the penis and scrotum as a rare but significant side effect of capecitabine.
Case presentation
We identified five cases of moderate to severe penis and scrotal erythrodysesthesia over a 2-year period at a large tertiary cancer center, representing an estimated incidence of 3.6% among male patients with rectal cancer who were treated with fluoropyrimidine-based chemoradiation within our institution.
Conclusions
Improved understanding of erythrodysesthesia involving the penis and scrotum can facilitate early identification and treatment of symptoms, and possibly prevent the discontinuation or delay of cancer treatment in patients treated with capecitabine and similar drugs. These clinical advances would improve and prolong patient quality of life during cancer treatment and prevent complications that result in hospitalization.
Avoid common mistakes on your manuscript.
Background
Neoadjuvant fluoropyrimidine-based chemoradiation is a standard of care treatment for patients with locally advanced rectal cancer [1,2,3]. Concurrent fluoropyrimidine therapy is preferentially administered as oral capecitabine, although continuous infusion 5-fluorouracil (5-FU) is an acceptable alternative [1, 4, 5]. One common adverse reaction associated with fluoropyrimidine is hand-foot syndrome (HFS), also known as palmar-plantar erythrodysesthesia (PPE). However, it should be noted that toxic erythema of chemotherapy (TEC) has become a more general terminology also utilized in the literature to characterize erythrodysesthesia and a variety of other cutaneous reactions triggered by chemotherapeutic agents. Up to 50% of patients receiving capecitabine report signs and symptoms of PPE [6, 7]. PPE is characterized by erythema, swelling, desquamation, ulceration, tingling, and pain that typically presents in a palmer and/or plantar distribution [6]. The rate and severity of PPE can depend on specific chemotherapy combinations, dose, schedule, and even cancer diagnosis [7].
Over a 2-year period at a tertiary cancer center, we retrospectively identified five cases of moderate to severe erythrodysesthesia involving the penis and/or scrotum in male patients with rectal cancer who were treated with neoadjuvant fluoropyrimidine-based chemoradiation. Each patient exhibited a scrotal/penile cutaneous presentation of erythrodysesthesia, ranging from moderate erythema and irritation to severe painful desquamation and ulceration. While erythrodysesthesia with genital involvement is mostly reported in patients treated with oral fluoropyrimidine capecitabine, we also report a case of erythrodysesthesia with genital involvement in a patient treated with bolus 5-FU/leucovorin-based chemoradiation. A comprehensive review of radiation treatment plans confirmed minimal radiation dose (Table 1), well below the threshold for dermatitis, to the penis and scrotum in these patients. In the patients whose capecitabine was held, their symptoms started to improve a few days later despite continuing radiotherapy.
There is very limited literature describing erythrodysesthesia with genital involvement due to fluoropyrimidine-based chemotherapy regimens, with or without concurrent radiation administration, as summarized in Table 2. Consequently, the incidence of erythrodysesthesia of the penis and scrotum is unknown. Intriguingly, there are no reports, to our knowledge, of genital erythrodysesthesia among women receiving fluoropyrimidine-based therapies. Given the rarity of this presentation, its incidence is likely underreported or unrealized in most clinical settings due to an incorrect differential diagnosis (e.g., allergic reaction, radiation dermatitis, or cellulitis) [8,9,10,11,12,13]. Based on our experience, patients are also hesitant to report these symptoms until they are quite severe given their sensitive nature.
This article has three aims: (1) describe the typical presentation of erythrodysesthesia with genital involvement, (2) estimate the incidence of genital erythrodysesthesia, and (3) demonstrate that the manifestation of erythrodysesthesia of the scrotum and penis secondary to fluoropyrimidine-based therapies (e.g., capecitabine and 5-FU) is more prevalent than reported in the literature.
Case presentations
From January 2021 through December 2023, we identified five patients with rectal cancer who developed erythrodysesthesia with genital involvement during capecitabine- or fluorouracil-based chemoradiation (Table 3). All five patients were men, consistent with literature reports that are also exclusively limited to male patients. During this same time period, 224 patients with rectal cancer, including 140 men and 84 women, were treated with fluoropyrimidine-based chemoradiation. The estimated reported incidence of erythrodysesthesia was 2.2% among all patients, and 3.6% among male patients with rectal cancer undergoing neoadjuvant fluoropyrimidine-based chemoradiation.
Case 1
Patient 1 is a 52-year-old White man with Mismatch Repair proficient (MMRp), cT3N0, and rectal adenocarcinoma that was 4 cm from the anal verge with possible sphincter involvement. He underwent induction chemoradiation to 54 Gy in 30 fractions with three-dimensional conformal radiotherapy (3D-CRT) and concomitant capecitabine 825 mg/m2 administered 5 days per week on days of radiotherapy. At the beginning of the fifth week of chemoradiation, he presented with painful, desquamation with purulent discharge to his scrotum (Fig. 1A). When questioned on symptom duration, the patient reported that he noticed mild scrotal irritation since the third week of chemoradiation that progressively worsened, but he failed to report it due to self-consciousness. His pain, which was exacerbated with walking, prevented him from performing the activities of daily living. Capecitabine was held for the sixth and final week of chemoradiation. Supportive skin care measures (including use of dermal wound cleanser, bacitracin, and dressings) were implemented daily in the clinic. His scrotal skin irritation began to improve a couple days after the cessation of capecitabine. Review of his radiation treatment plan confirmed no to minimal dose to the scrotum (Fig. 1B and Table 1). Despite his grade 3 erythrodysesthesia with genital involvement, he was able to complete all radiation treatments.
He then went on to receive consolidative chemotherapy with fluorouracil, irinotecan, and oxaliplatin (FOLFIRINOX) without reemergence of scrotal erythrodysesthesia.
Case 2
Patient 2 is a 46-year-old Asian man with MMRp, cT3bN0, rectal adenocarcinoma that was 6–8 cm from the anal verge. He underwent induction chemoradiation to 54 Gy in 30 fractions with 3D-CRT and concomitant capecitabine 825 mg/m2 administered 5 days per week on days of radiotherapy. At the beginning of the fifth week of chemoradiation, he developed left testicular pressure and hyperpigmentation to the penis shaft and scrotum. During the sixth week, he reported worsening significant pain and edema of his penis and irritation of his scrotum. Review of his radiation treatment plan confirmed no to minimal dose to the penis and scrotum (Table 1). He was able to complete chemoradiation without interruption or capecitabine dose reduction despite developing grade 2 erythrodysesthesia with genital involvement. The patient was referred to dermatology, and his symptoms were managed conservatively with topical silver sulfadiazine, triamcinolone, aloe vera, and morphine gel applied to non-occlusive dressings. His symptoms resolved shortly after he completed chemoradiation—well in advance of improvement of his radiation side effects. He subsequently went on to receive consolidative capecitabine and oxaliplatin (CAPEOX) a month later. However, due to transient visual disturbance to his right eye after one cycle, oxaliplatin was omitted, and he completed chemotherapy with capecitabine alone. During this period, he experienced a re-emergence of his genital erythrodysesthesia, but this time, he also experienced erythrodysesthesia to his hands and soles of his feet, which began prior to his fourth cycle of capecitabine. His symptoms progressed from mild erythema and discomfort to eventual painful skin sloughing. This resulted in him having to hold capecitabine for 1 week to facilitate healing with topical clobetasol and celecoxib as needed, prior to completing his last six days of treatment. Following completion of treatment, these symptoms also eventually resolved.
Case 3
Patient 3 is a 53-year-old White man with MMRp, cT4bN1, moderately differentiated, invasive adenocarcinoma that was 2 cm from the anal verge. He was treated with induction CAPEOX without complications. He then underwent consolidative chemoradiation to 54 Gy in 27 fractions with volumetric modulated arc therapy (VMAT) and concomitant capecitabine 825 mg/m2 administered 5 days per week on days of radiotherapy. During his fourth week of chemoradiation, he reported mild erythema and irritation to the tip of his penis. By the fifth week of chemoradiation, he developed pain, tenderness, and skin sloughing with open blisters on his penile glans (Fig. 2A). Review of his radiation treatment plan noted a mean dose of 19.8 Gy to the penis and 7.5 Gy to the scrotum (Fig. 2B and Table 1). He was followed by dermatology for management of his penile skin erosion. The infectious work-up during this time was unremarkable. Dermatological management during this time included ketoconazole wash daily, in addition to topical ciclopirox and mupirocin twice daily to the ulcerated penile glans. While the last four doses of capecitabine were held given his grade 3 erythrodysesthesia with genital involvement, he was able to complete all radiation treatments.
Case 4
Patient 4 is a 68-year-old White male with cT4bN+ rectal adenocarcinoma that was 3.5 cm from the anal verge. He completed eight cycles of induction fluorouracil, leucovorin, and oxaliplatin (FLOX) without dermatological complication. He then went on to receive consolidative chemoradiation to 54 Gy in 30 fractions with 3D-CRT and concomitant bolus 5-FU (425 mg/m2) and leucovorin (20 mg/m2). During his fifth week of chemoradiation, he developed erythema and irritation to the penile and scrotal skin to which topical silver sulfadiazine and an antifungal cream were prescribed for management. In the following week, this progressed to desquamation (including fissuring), bleeding, and severe pain to the penis (Fig. 3A). Review of his radiation treatment plan confirmed no to minimal dose to the scrotum (Fig. 3B and Table 1). Dermatology evaluation at the end of treatment confirmed that his symptoms were consistent with erythrodysesthesia due to 5-FU. The patient continued topical silver sulfadiazine but was also prescribed topical mometasone for dermatological management and oral tramadol for pain management. Despite developing grade 3 erythrodysesthesia with genital involvement, he had already completed all chemoradiation treatments. His symptoms resolved a few weeks after completing chemoradiation.
Case 5
Patient 5 is a 67-year-old White male with synchronous cT3bN+ rectal adenocarcinoma and stage IV cecal adenocarcinoma metastatic to the liver. He completed induction FOLFOX (first-line) and fluorouracil, leucovorin, and irinotecan (FOLFIRI) with bevacizumab (second-line), followed by right hemicolectomy and liver wedge resection. He then went on to receive consolidative chemoradiation to 54 Gy in 30 fractions with 3D-CRT and concomitant capecitabine 825 mg/m2 administered 5 days per week on days of radiotherapy. During his fifth week of chemoradiation, he developed severe erythema, pain, and drainage along the scrotal skin. He was prescribed acetaminophen with codeine for pain management and advised by his local dermatologist to manage scrotal skin changes with topical hydrocortisone. However, he was eventually hospitalized with worsening scrotal skin pain and desquamation during his sixth week of chemoradiation. During his inpatient stay, necrotizing fasciitis and cellulitis were ruled out. Diagnostic work-up indicated he likely experienced a chemotherapy-induced skin reaction. The patient was followed by dermatology and infectious disease during his admission and was started on empiric intravenous and oral antibiotics, as well as topical silver sulfadiazine. While the last 3 days of capecitabine were held given his grade 3 erythrodysesthesia with genital involvement, he was able to complete all radiation treatments. His symptoms began to improve following discontinuation of capecitabine.
Discussion and conclusions
The exact pathophysiology of PPE secondary to fluoropyrimidine administration is not fully understood. One theory suggests possible genetic polymorphism of specific genes—thymidylate synthase and dihydropyrimidine dehydrogenase (DPD)—may potentiate an individual’s intolerance to fluoropyrimidines like capecitabine and 5-FU and increase the potential for developing symptoms of PPE [14]. We do not routinely test for DPD deficiency at our center unless there are clinical symptoms suggestive of DPD deficiency. Another theory posits pathophysiological processes that facilitate the accumulation of fluoropyrimidine-based drugs to skin surfaces through eccrine glands, forming damaging free radicals in the upper epidermis that result in skin erythema or erosion [15]. Although the pathophysiology remains unclear, the association of PPE with capecitabine and 5-FU is well established [6, 7].
While PPE is a common adverse reaction attributed to fluoropyrimidine, rates of grade 3 PPE during chemotherapy and chemoradiation are fortunately low as dose reduction can help prevent grade 1–2 reactions from progressing to grade 3 reactions. In the National Surgical Adjuvant Breast and Bowel Project (NSABP) R-04 study, which demonstrated the equivalence of 5-FU and capecitabine-based chemoradiation, the rate of grade 3 PPE during chemoradiation was dose and schedule dependent [2]. When oral capecitabine 825 mg/m [2] was administered twice per day 7 days per week throughout the course of radiotherapy, the rate of grade 3 PPE was 3.5%. In comparison, when the daily dose of capecitabine remained the same but the frequency of capecitabine treatment was reduced from 7 days per week to 5 days per week, the rate of grade 3 PPE was 0.3% [2]. Similarly, in the Xeloda in Adjuvant Colon Cancer (X-ACT) study, which demonstrated the equivalence of oral capecitabine and bolus-fluorouracil plus leucovorin in the adjuvant setting for patients with stage III colon cancer, the rate of grade 3 PPE was 1.7% in patients treated with capecitabine at a dose of 1250 mg/m2 given twice daily on days 1 through 14 every 21 days [16]. Additionally, the International Duration Evaluation of Adjuvant Chemotherapy (IDEA) study found increased likelihood of developing grade 3 PPE in patients with stage III colon cancer treated with 6 months as compared to 3 months (2.6% vs. 0.7%) of adjuvant capecitabine [17]. As the rate of grade 3 PPE is dose and schedule dependent, early PPE identification and fluoropyrimidine dose modification can likely prevent a grade 1–2 reaction from progressing to a more severe grade 3 reaction.
This is the first report, to our knowledge, to calculate an estimated incidence for erythrodysesthesia with genital involvement (2.2% among all patients and 3.6% among male patients with rectal cancer treated with fluoropyrimidine-based chemoradiation). While our series is limited to patients undergoing fluoropyrimidine-based chemoradiation for rectal cancer, and patient identification for this case series was based on recall of cases occurring during January 2021 through December 2023, we believe that this incidence can reasonably be extrapolated to all patients treated with fluoropyrimidine-based systemic therapies. Our data suggests that erythrodysesthesia with genital involvement is more common than previously believed, and actual incidence may be higher due to underreporting or lack of clinical appreciation of its occurrence. It is important to consider erythrodysesthesia with genital involvement in male patients treated with fluoropyrimidines to allow early identification and intervention. Early intervention may mitigate progression to grade 3 toxicity, limit discontinuation or interruption of cancer treatment, improve and prolong patient quality of life, and prevent hospitalization due to complications related to infection, pain, and ulceration.
While the Common Terminology Criteria for Adverse Events (CTCAE) version 5 summarized in Table 4 specifically includes PPE, there is no formal grading criteria for erythrodysesthesia involving the penis and/or scrotum [18]. Therefore, the consideration of a more inclusive grading system that describes scrotal and penile erythrodysesthesia would further assist clinicians to identify genital erythrodysesthesia early on in therapy (e.g., at a grade 1 presentation). Indeed, in this case series, we extrapolated the CTCAE for PPE to systematically grade erythrodysesthesia with genital involvement.
Finally, with an increased awareness and identification of genital erythrodysesthesia, management goals should include a possible dose reduction or discontinuation of the specific fluoropyrimidine drug in conjunction with supportive skin and pain care measures in order to prevent progression of symptoms (i.e., to grade 2 or 3) and prevent interruption of therapy. Though there is no established standard to manage symptoms of PPE, literature cites drug interruption or dose reduction as the mainstay of treatment for TEC, based on the severity of reaction. Alternative supportive interventions may also include high potency topical corticosteroids, wound care for ulcerations, analgesics for pain management (e.g., opioids or gabapentin), and emollients and topical keratolytics (e.g., urea or salicylic acid) for area of keratosis [19, 20].
Data availability
No datasets were generated or analyzed during the current study.
References
NCCN (NCCN) (2023) NCCN clinical practice guidelines in oncology rectal cancer. https://www.nccn.org/professionals/physician_gls/pdf/rectal.pdf. Accessed 18 Oct 2023
O’Connell MJ, Colangelo LH, Beart RW et al (2014) Capecitabine and oxaliplatin in the preoperative multimodality treatment of rectal cancer: surgical end points from National Surgical Adjuvant Breast and Bowel Project trial R-04. J Clin Oncol 32(18):1927–1934. https://doi.org/10.1200/JCO.2013.53.7753
Sauer R, Becker H, Hohenberger W et al (2004) Preoperative versus postoperative chemoradiotherapy for rectal cancer. N Engl J Med 351(17):1731–1740. https://doi.org/10.1056/NEJMoa040694
O’Connell MJ, Martenson JA, Wieand HS et al (1994) Improving adjuvant therapy for rectal cancer by combining protracted-infusion fluorouracil with radiation therapy after curative surgery. N Engl J Med 331(8):502–507. https://doi.org/10.1056/NEJM199408253310803
Allegra CJ, Yothers G, O’Connell MJ et al (2015) Neoadjuvant 5-FU or capecitabine plus radiation with or without oxaliplatin in rectal cancer patients: a phase III randomized clinical trial. J Natl Cancer Inst. https://doi.org/10.1093/jnci/djv248
Saif MW (2011) Capecitabine and hand-foot syndrome. Expert Opin Drug Saf 10(2):159–169. https://doi.org/10.1517/14740338.2011.546342
Webster-Gandy JD, How C, Harrold K (2007) Palmar-plantar erythrodysesthesia (PPE): a literature review with commentary on experience in a cancer centre. Eur J Oncol Nurs 11(3):238–246. https://doi.org/10.1016/j.ejon.2006.10.004
Sapp CM, DeSimone P (2007) Palmar-plantar erythrodysesthesia associated with scrotal and penile involvement with capecitabine. Clin Colorectal Cancer 6(5):382–385. https://doi.org/10.3816/CCC.2007.n.008
Lee YJ, Lee HJ, Jeong KC, Kang JG, Lee SH, Kim YT (2009) An unusual presentation of hand-foot syndrome at the hidden area: the scrotum and penis. Acta Oncol 48(4):636–637. https://doi.org/10.1080/02841860802698858
Fleta-Asin B, Alcantara-Gonzalez J, Alonso-Castro L, Truchuelo-Diez M, Jaen-Olasolo P (2011) Genital erythrodysesthesia as a severe manifestation of capecitabine therapy: a report of 3 cases. Arch Dermatol 147(9):1123–1124. https://doi.org/10.1001/archdermatol.2011.257
Ljubojevic Hadzavdic S, Stulhofer Buzina D, Murtezani I, Skerlev M (2017) Unusual scrotal and penile ulcerations together with palmar-plantar erythrodysesthesia syndrome in a patient with metastatic colon carcinoma treated with capecitabine. J Eur Acad Dermatol Venereol 31(6):e304–e306. https://doi.org/10.1111/jdv.14090
Hu HP, Corkum MT, Perera F (2018) Palmar-plantar erythrodysesthesia with genital involvement secondary to capecitabine chemoradiotherapy: a case report. Cureus 10(12):e3704. https://doi.org/10.7759/cureus.3704
Dricken J, Pettke E, Griffin JA, Li HY, Mehta V (2020) Scrotal and penile erythrodysesthesia associated with neoadjuvant capecitabine chemoradiation. Cureus 12(4):e7724. https://doi.org/10.7759/cureus.7724
Lin S, Yue J, Guan X et al (2019) Polymorphisms of MTHFR and TYMS predict capecitabine-induced hand-foot syndrome in patients with metastatic breast cancer. Cancer Commun (London) 39(1):57. https://doi.org/10.1186/s40880-019-0399-z
Martschick A, Sehouli J, Patzelt A et al (2009) The pathogenetic mechanism of anthracycline-induced palmar-plantar erythrodysesthesia. Anticancer Res 29(6):2307–2313
Twelves C, Wong A, Nowacki MP et al (2005) Capecitabine as adjuvant treatment for stage III colon cancer. N Engl J Med 352(26):2696–2704. https://doi.org/10.1056/NEJMoa043116
Grothey A, Sobrero AF, Shields AF et al (2018) Duration of adjuvant chemotherapy for stage III colon cancer. N Engl J Med 378(13):1177–1188. https://doi.org/10.1056/NEJMoa1713709
Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 (2017)
Miller KK, Gorcey L, McLellan BN (2014) Chemotherapy-induced hand-foot syndrome and nail changes: a review of clinical presentation, etiology, pathogenesis, and management. J Am Acad Dermatol 71(4):787–794. https://doi.org/10.1016/j.jaad.2014.03.019
Shi VJ, Levy LL, Choi JN (2016) Cutaneous manifestations of nontargeted and targeted chemotherapies. Semiars in Oncology 43(3):419–425. https://doi.org/10.1053/j.seminoncol.2016.02.018
Acknowledgements
We are grateful to the patients presented in this article. Written informed consent was obtained from the patients to use photographs and treatment plans for publications. The authors would also like to thank Jennifer Huber, PhD, for editorial support.
Funding
This work was supported in part by the National Institutes of Health/National Cancer Institute (NIH/NCI) Memorial Sloan Kettering Cancer Center (MSK) Support Grant (P30 CA008748). Paul B. Romesser is also supported by an NIH/NCI grant (K08CA255574).
Ethics declarations
Ethics approval and consent to participate
This retrospective analysis was approved by the institutional review board with a waiver of informed consent. Medical records were reviewed for patients with rectal adenocarcinoma who were treated with fluoropyrimidine-based chemoradiation from January 2021 through December 2023 at our institution.
Consent for publication
All patients provided written consent for publication of their clinical details and/or clinical images.
Competing interests
Angela Adames serves on the Oncology Nursing Certification Corporation (ONCC) test development committee for the Oncology Certified Nurses (OCN®) examination, is this committee’s current chair, and receives travel and lodging support from ONCC outside of the submitted work. Leonard B. Saltz served as a consultant for Genor Biopharma Holdings Ltd. and Optimal Cancer Care Alliance (OCCA) and received research funding from Taiho Pharmaceutical outside of the submitted work. Julio Garcia-Aguilar has provided professional services to Ethicon and Intuitive Surgical Inc. outside of the submitted work. Andrea Cercek has received grants and contracts from GlaxoSmithKline and Seagen Inc. and has received honoraria from Bayer, GI Therapeutics, GlaxoSmithKline, Janssen Biotech, Merck, Pfizer Pharmaceuticals LLC, Roche, Amgen, Abbivie, and Seagen Inc. outside the submitted work. Christopher Crane serves as a consultant for TriSalus Life Siences. He has received research funding from Elekta outside of the submitted work. J. Joshua Smith received travel support for fellow education from Intuitive Surgical. He also served as a clinical advisor for Guardant Health as a clinical advisor for Foundation Medicine and as a consultant and speaker for Johnson and Johnson. He serves as a clinical advisor and consultant for GSK outside of the submitted work. Abraham Wu has provided consulting services to CivaTech Oncology, Inc., MORE Health, Inc., Nanovi A/S, and Simphotek, Inc. outside of the submitted work. Alina Markova has provided consulting services to ADC Therapeutics, Alira Health, AstraZeneca, Protagonist Therapeutics, OnQuality, and Janssen. She has also received research funding from Amryt Pharma, AstraZeneca, Incyte Corporation, Kintara Therapeutics, Novocure, and royalties from UptoDate outside of the submitted work. Paul B. Romesser received research funding and serves as a consultant for EMD Serono, receives research funding from XRAD Therapeutics, is a consultant for Faeth Therapeutics, is a consultant for Natera, and is a volunteer on the advisory board for the HPV Alliance and Anal Cancer Foundation non-profit organizations outside of the submitted work. All other authors have no conflicts of interest to declare.
Additional information
Publisher's Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Rights and permissions
Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.
About this article
Cite this article
Adames, A., O’Brien, D.R., Kelly, A.R. et al. Penile-scrotal erythrodysesthesia among rectal cancer patients receiving fluoropyrimidine-based chemoradiation: a case report series. Int J Colorectal Dis 39, 75 (2024). https://doi.org/10.1007/s00384-024-04647-2
Accepted:
Published:
DOI: https://doi.org/10.1007/s00384-024-04647-2